Beacon Therapeutics Holdings Limited a leading ophthalmic gene therapy company with a mission to save and restore the vision of patients with blinding retinal diseases, announced that the U.S. Food and Drug Administration (FDA) has granted...
Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose-limiting toxicity, announced that it has secured a $30 million financing to advance the development of LUT014, an...
Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), today...
Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, today announces achievement of clinical validation through its Phase 2a clinical trial in psoriasis with fully proprietary...
Chromatin Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced its ESO-T01 in vivo CAR-T candidate into clinical trials. ESO-T01 is the first in vivo B-cell maturation antige. (BCMA) CAR-T...
Modular Devices, a leading provider of mobile and modular cleanroom and medical imaging solutions, today announces the appointment of two new members of the business development team for their cleanrooms division: Jason Thompson and Stephanie...
Outrun Therapeutics ("Outrun"), the E3 ligase inhibitor and protein stabilisation specialist, announces the appointment of Matthew Fyfe as its Chief Scientific Officer. Matthew has over 25 years' experience in drug discovery and development across...
Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, today announced its launch with $120 million in funding. The company was founded by Monograph Capital in...
Mediar Therapeutics, Inc., a clinical stage biotechnology company advancing a portfolio of first-in-class therapies designed to halt fibrosis progression, announced a global licensing agreement with Eli Lilly and Company to advance MTX-463 into a...
Dr. Howard Murad, a 1962 graduate of Long Island University's Arnold & Marie Schwartz College of Pharmacy and Health Sciences and an internationally recognized innovator in the science of skin care, is establishing the Dr. Howard Murad '62...
In a milestone for cellular research, eMBR Genomics and Axio BioPharma announce the first commercial availability of MKLP1 Pro™ antibodies, KIF23 gene – the same tools used by the world's leading Midbody Remnants (MBRs) researchers. This strategic...
Eden has launched the world's first compounded semaglutide gummy. Designed to deliver the benefits of GLP-1 medications in a convenient, needle-free format, this innovative format reimagines how individuals approach GLP-1 programs in the United...
Orthogon Therapeutics, a developer of novel antiviral medicines, announced the closing of an oversubscribed financing round, exceeding its $5M target and bringing total funding to over $25M. This funding will accelerate the development of its...
Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT012, for treating liver and intrahepatic bile duct cancer (HCC/ICCA). Achieved in November...
UroMems, a global medical technology company developing the first smart automated implant to treat stress urinary incontinence (SUI), today announced the appointment of medical device veteran Rinda Sama to its board of directors. "We are thrilled...
BioArctic AB's partner Eisai announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved Leqembi (lecanemab) for the treatment of early Alzheimer's disease (AD)1. Leqembi selectively binds to...
SciTech Development, a clinical-stage pharmaceutical company focused on advancements in cancer treatment, is excited to share promising updates from its clinical trial of ST-001 nanoFenretinide (ST-001). Preliminary Trial Findings: Preliminary...
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced that the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI®" has...
The latest progress in the clinical trial of BH3120, an innovative immunotherapy jointly developed by Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical, was recently presented at a major global academic conference, drawing significant...
Animal models expressing loss-of-function mutations in mitochondrial DNA enable the investigation of mitochondrial gene function and related disorders. In a recent study, scientists from Korea University described the impact of a mitochondrial ND5...